Please ensure Javascript is enabled for purposes of website accessibility


Big things are happening at Ogier. Change is embedded in everything we do. It is redefining our talent, our ways of working, our platforms of delivery, our culture.



We have the expertise to handle the most demanding transactions. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies means we add real value to clients’ businesses.

View all services

Business Services Team

View all Business Services Team


Our sector approach relies on smart collaboration between teams who have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients to see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier advises Conduit Pharmaceuticals in US$720 million merger with SPAC Murphy Canyon Acquisition Corp


26 September 2023

Cayman Islands

1 min read

Ogier acted as Cayman Islands counsel to Conduit Pharmaceuticals Limited in its US$720 million merger with Murphy Canyon Acquisition Corp, a publicly traded special purpose acquisition company (SPAC).

The deal, which was announced in November 2022, closed on 22 September 2023 and the shares commenced trading on Nasdaq on 25 September 2023. At the start of trading, Conduit had a pro forma enterprise value of approximately US$720 million.

Conduit is a life science company that does not follow the traditional pharma/biotech business model whereby companies shepherd their assets through regulatory approval. Conduit acquires assets that are phase II-ready and then seeks an exit through third-party license deals following successful clinical trials.

The Ogier team was led by partner Giorgio Subiotto, with managing associate Graeme Loarridge and associate Jasjit Grewal. They advised Conduit Pharmaceuticals Limited on all Cayman Islands aspects of the transaction, working alongside US counsel, Thompson Hine LLP, and US counsel to Murphy Canyon Acquisition Corp, Sichenzia Ross Ference LLP.

Ogier has assisted Conduit Pharmaceuticals Limited with Cayman Islands law advice since its incorporation. Giorgio Subiotto commented: "It has been great to be part of Conduit's growth story. Conduit’s business model is trailblazing – its lean and focused approach to developing medical drugs that others have successfully shepherded through phase I trials allows it to develop potentially life-saving drugs that may otherwise never make it past phase I and see the light of day. This latest milestone provides Conduit with a great platform from which to continue this fantastic work. We are delighted to have been able to assist Conduit."

No Content Set